Low-dose doxorubicin in the management of advanced carcinoma of the prostate.
Twenty-one patients with advanced metastatic carcinoma of the prostate, no longer responsive to conventional therapy, were treated with weekly low-dose doxorubicin (Adriamycin). Twelve had an impressive subjective response in terms of pain relief and improved performance status and in nine this was maintained for 3 or more months.
D004317:Doxorubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D004317:Doxorubicin